{"entity":{"id":"atebimetinib","kind":"drug","name":"Atebimetinib","aka":[],"tldr":"Atebimetinib is an experimental small-molecule drug from Immuneering in phase 3 trials for pancreatic ductal adenocarcinoma, aimed at MEK1/2.","summary":"Atebimetinib is a small-molecule drug developed by Immuneering. Its target is MEK1/2 (the sponsor names MEK). The sponsor states: Oral, once-daily 'Deep Cyclic Inhibitor' of MEK that pulses target inhibition rather than suppressing it continuously. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07562152 (Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma), in pancreatic ductal adenocarcinoma. The largest, NCT07562152, plans to enrol 510 participants with primary completion expected 2028-06. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Atebimetinib","url":"https://clinicaltrials.gov/search?intr=Atebimetinib"},{"label":"Sponsor page","url":"https://www.immuneering.com/pipeline"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":["mek"],"drugs":[],"companies":["immuneering"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07562152"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"small molecule","mechanism":"Oral, once-daily 'Deep Cyclic Inhibitor' of MEK that pulses target inhibition rather than suppressing it continuously.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/atebimetinib/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"target":[{"id":"mek","kind":"target","name":"MEK1/2","route":"/targets/mek/"}],"company":[{"id":"immuneering","kind":"company","name":"Immuneering","route":"/companies/immuneering/"}],"trial":[{"id":"nct07562152","kind":"trial","name":"Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","route":"/trials/nct07562152/"}]}}